Clinical trials: Processes, Metabolic
Chronic Kidney Disease, Type 2 Diabetes
Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)
A Phase II, Open-Label Safety and Efficacy Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (RMTX-CL001).
- Trial name
- RMCL-CL001 (NCT02525263)
- Testing
- Neo-Kidney Augment
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Prokidney
Hyperphosphatemia, End-stage Renal Disease
Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
The objective of this study is to see if KRX-0502 (ferric citrate) is safe and effective as a dietary phosphate binder in controlling and managing serum phosphorus levels in patients with end-stage renal disease (ESRD).
- Conditions
- Hyperphosphatemia, End-stage Renal Disease, Renal Failure Chronic Requiring Hemodialysis
- Trial name
- NCT00967993
- Testing
- ferric citrate
- Where
- 3 sites in Israel
- Volunteers
- 22 people
- Sponsor
- Keryx Biopharmaceuticals
Chronic Obstructive Pulmonary Disease
Roflumilast on Markers of Bone Metabolism and Endothelial Function in COPD
Our primary hypothesis is that Roflumilast (500 μcg, once daily) will significantly decrease surrogate markers of bone metabolism and early cardiovascular disease in individuals with moderate to severe airflow obstruction and a…
- Trial name
- NCT01745848
- Testing
- Roflumilast
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Pittsburgh
Urea Cycle Disorders
Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)
This non-randomized, open-label study was approximately one year in duration and consisted of a short term NaPBA to HPN-100 switchover part involving two overnight stays followed by a 12-month long term treatment period involving…
- Trial name
- NCT01347073
- Testing
- HPN-100
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- Amgen
Diabetic Kidney Disease, Hyperuricemia
Uric Acid Lowering Trial in Youth Onset T2D
Adolescents and young adults with youth-onset type 2 diabetes (T2D) are disproportionally impacted by hyperuricemia compared to non-diabetic peers and youth with type 1 diabetes (T1D).
- Conditions
- Diabetic Kidney Disease, Hyperuricemia, Diabetes, Diabetes Mellitus, Type 2
- Trial name
- ULTRA-T2D (NCT03899883)
- Testing
- Pegloticase 8 MG/ML [Krystexxa]
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Colorado, Denver
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
This phase II trial studies how well giving fludarabine phosphate, melphalan, and low-dose total-body irradiation (TBI) followed by donor peripheral blood stem cell transplant (PBSCT) works in treating patients with hematologic…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01529827
- Testing
- fludarabine phosphate, melphalan, total-body irradiation
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Roswell Park Cancer Institute
Chronic Kidney Disease, Vitamin D Deficiency
Cholecalciferol (Vitamin D3) Therapy in Chronic Kidney Disease (CKD) Subjects
This is a 12 week pilot and feasibility study with an enrollment goal of 30 subjects. Half of the subjects will be randomized to vitamin D3 and the other half will receive a placebo.
- Trial name
- NCT00427037
- Testing
- Cholecalciferol
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Atlanta VA Medical Center
Mild Dehydration
The Effect of Acute Mild Dehydration on Blood Pressure Control
The goal of this project is determine how acute mild dehydration impacts blood pressure control at rest and during static exercise.
- Trial name
- NCT03560869
- Testing
- Normal hydration, Dehydration
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- University of Delaware
Calciphylaxis, Calcific Uremic Arteriolopathy
Phase 2 Study With SNF472 in Calciphylaxis Patients
To evaluate the effect of SNF472 on top of standard of care on promoting wound healing and other parameters of therapeutic response in haemodialysis patients with calciphylaxis (calcific uraemic arteriolopathy, CUA).
- Trial name
- NCT02790073
- Testing
- SNF472
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 14 people
- Sponsor
- Sanifit Therapeutics S. A.
Sepsis, Kidney Injury
Thiamine as a Renal Protective Agent in Septic Shock
This is a randomized, double-blind, placebo controlled study to investigate the effect of intravenous thiamine (vitamin B1) on renal function in septic shock.
- Conditions
- Sepsis, Kidney Injury, Thiamine Deficiency
- Trial name
- NCT03550794
- Testing
- Thiamine Hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 95 people
- Sponsor
- Beth Israel Deaconess Medical Center
Diabetes
Harnessing Health IT for Self-Management Support and Medication Activation in a Medicaid Health Plan
To measure the effects of a Medical health plan-directed automated telephone self-management support system (ATSM) on patient outcomes among ethnically diverse health plan enrollees with diabetes.
- Trial name
- SMARTSteps (NCT00683020)
- Testing
- ATSM Intervention
- Where
- United States
- Volunteers
- 362 people
- Sponsor
- University of California, San Francisco
Obesity, Visceral, Obesity; Endocrine
Study of Lipolysis of Visceral Reserve Fat Using Tecar Therapy.
The Scope of this study is to assess the visceral and subcutaneous fat loss in patients having Tecar (Radiofrequency) Therapy and its effects on other anthropometric variables, adipokines and inflammation.
- Trial name
- NCT06377358
- Testing
- Tecar Therapy
- Where
- Spain
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- CAPENERGY MEDICAL, SL
Mucopolysaccharidosis IIIB
Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)
Study to evaluate the safety and tolerability of intravenous (IV) administration of SBC-103 in participants with mucopolysaccharidosis III, type B (MPS IIIB, Sanfilippo B) with evaluable signs or symptoms of developmental delay.
- Trial name
- NCT02324049
- Testing
- SBC-103
- Where
- 4 sites in United States, Spain and 1 more
- Volunteers
- 11 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Frailty, Weight, Body
Effect of Behavioral Lifestyle Intervention on Frailty in Older Adults With Diabetes
The study team want to see if changes in lifestyle and behaviors and self-monitoring of diet and physical activity in older adults who have type 2 Diabetes (T2D) may help to prevent or reduce frailty.
- Conditions
- Frailty, Weight, Body, Type 2 Diabetes
- Trial name
- NCT04440449
- Testing
- Lifestyle App, Look AHEAD behavior lifestyle intervention, Abbreviated Look AHEAD behavior lifestyle intervention
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Weight Change, Body
Healthy Homes/Healthy Families (HH/HF) Intervention in 2-1-1 Callers
This trial will evaluate a healthy eating and weight gain prevention intervention for delivery through calls to the 2-1-1 number.
- Trial name
- NCT04373434
- Testing
- Health Homes/Healthy Families (HH/HF) Intervention, Control
- Where
- United States
- Volunteers
- 512 people
- Sponsor
- Emory University
Hyperkalaemia, Chronic Kidney Disease
Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study
This is an open-label, randomised study in participants with chronic kidney disease (CKD) treated for hyperkalaemia (HK) whilst in hospital.
- Trial name
- CONTINUITY (NCT05347693)
- Testing
- Sodium Zirconium Cyclosilicate (SZC), Local standard of care
- Where
- 28 sites in Belgium, France and 4 more
- Volunteers
- 186 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes
The study compares two semaglutide medicines and looks at how well they control blood sugar levels, in participants with type 2 diabetes (T2D).
- Trial name
- NCT05478252
- Testing
- Semaglutide J, Semaglutide B
- Where
- 104 sites in United States, Canada and 3 more
- Volunteers
- 388 people
- Sponsor
- Novo Nordisk A/S
Cystic Fibrosis, Prediabetes
Prevention of Cystic Fibrosis Diabetes
Acute systemic hyperglycemia causes oxidative stress and a pro-inflammatory response. The pro-inflammatory cytokines induced by hyperglycemia are toxic to islet insulin producing cells, and thus worsen glucose intolerance.
- Trial name
- Prevent (NCT00967798)
- Testing
- Sitagliptin
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Emory University
Amorphous, Eosinophilic, and Acellular Deposit, Constipation
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment.
- Conditions
- Amorphous, Eosinophilic, and Acellular Deposit, Constipation, Diarrhea, Early Satiety
- Trial name
- NCT03499808
- Testing
- Isatuximab, Laboratory Biomarker Analysis
- Where
- 345 sites in United States
- Volunteers
- 43 people
- Sponsor
- SWOG Cancer Research Network
Nonalcoholic Fatty Liver Disease, NAFLD
Rifaximin in Fatty Liver Disease
TITLE Rifaximin in Fatty Liver Disease (RiFL) DESIGN Open-label pilot study HYPOTHESIS Reduction in gut flora by the antibiotic Rifaximin reduces hepatic inflammation in Non-Alcoholic Steatohepatitis (NASH).
- Conditions
- Nonalcoholic Fatty Liver Disease, NAFLD, Nonalcoholic Steatohepatitis
- Trial name
- RiFL (NCT01355575)
- Testing
- Rifaximin
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Imperial College London